Healthcare News - Vital Signs - The Analysts Perspective - April Issue

Regular Price: USD 450.00

Special Price USD 405.00

10% OFF

* Required Fields

Regular Price: USD 450.00

Special Price USD 405.00


Be the first to review this product

This issue of Vital Signs, released on May 1, 2014, discusses the mega deals brewing in the pharma/biotech industry, Pfizer Inc’s Xalkori for non-small cell lung cancer, Novartis' halt on RNAi development efforts, the high-ranked Malaysian healthcare system, Roche's acquisition of IQuum's Liat Analyzer, and Bio-Rad's acquisition of GnuBio.

Table of Contents

Healthcare News - Vital Signs - The Analyst's Perspective - April IssueVital Signs - April 30 2014This week's issue

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.